Alyeska Investment Group, L.P. Cure Vac N.V. Transaction History
Alyeska Investment Group, L.P.
- $25 Billion
- Q4 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Cure Vac N.V. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 500,000 shares of CVAC stock, worth $1.53 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
500,000
Previous 400,000
25.0%
Holding current value
$1.53 Million
Previous $1.18 Million
44.98%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding CVAC
# of Institutions
86Shares Held
10.5MCall Options Held
75.5KPut Options Held
33.5K-
Black Rock Inc. New York, NY2.25MShares$6.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.65MShares$5.04 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$4.8 Million10.6% of portfolio
-
Ubs Group Ag577KShares$1.77 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct441KShares$1.35 Million0.0% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $574M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...